Literature DB >> 389162

In vitro correction of erythrocyte glucose 6-phosphate dehydrogenase (G6PD) deficiency.

A Morelli, U Benatti, F Salamino, B Sparatore, M Michetti, E Melloni, S Pontremoli, A De Flora.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 389162     DOI： 10.1016/0003-9861(79)90278-9

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN： 0003-9861            Impact factor:   4.013


× No keyword cloud information.
  6 in total

1.  Conversion of encapsulated 5-fluoro-2'-deoxyuridine 5'-monophosphate to the antineoplastic drug 5-fluoro-2'-deoxyuridine in human erythrocytes.

Authors:  A De Flora; E Zocchi; L Guida; C Polvani; U Benatti
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

Review 2.  Carrier erythrocytes. Clinical pharmacokinetic considerations.

Authors:  M Tonetti; A De Flora
Journal:  Clin Pharmacokinet       Date:  1993-11       Impact factor: 6.447

3.  G6PD Cagliari: a new low activity glucose 6-phosphate dehydrogenase variant characterized by enhanced intracellular lability.

Authors:  A Morelli; U Benatti; L Guida; A De Flora
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

4.  Encapsulation of adriamycin in human erythrocytes.

Authors:  A De Flora; U Benatti; L Guida; E Zocchi
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

5.  Kinetic properties of hexose-monophosphate dehydrogenases. II. Isolation and partial purification of 6-phosphogluconate dehydrogenase from rat liver and kidney cortex.

Authors:  F J Corpas; L García-Salguero; J B Barroso; F Aranda; J A Lupiáñez
Journal:  Mol Cell Biochem       Date:  1995-03-23       Impact factor: 3.396

Review 6.  Erythrocytes as Carriers of Therapeutic Enzymes.

Authors:  Bridget E Bax
Journal:  Pharmaceutics       Date:  2020-05-08       Impact factor: 6.321
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.